AKR1C3 and posterior cortical atrophy: To the best of our knowledge, there is no report of AKR1C3 expression after ARAT treatment; however, AKR1C3 activation, both in vitro and in vivo, using PCa cell lines, has been shown as a factor of resistance against ARATs [25,26].